Streetbeat News

Regulatory

EWC

The Bank of Canada has decided to keep its interest rates unchanged, maintaining the current monetary policy stance. This decision reflects the central bank's assessment of the economic conditions and inflation outlook.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:45 pm

SPY

A US court has struck down the SEC's rule requiring hedge funds to disclose their fees. This decision could impact transparency and investor confidence in the hedge fund industry.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:42 pm

KSCP

Knightscope has been granted an extension by the Nasdaq Hearings Panel to regain compliance with the bid price rule.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:36 pm

APDN

Applied DNA Sciences has received a Notice of Allowance from the USPTO for its patent application titled 'Compositions and Methods for RNA Synthesis.' This development could enhance the company's intellectual property portfolio and potentially open new revenue streams.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:11 pm

WNW

Meiwu Technology has received a notification letter from Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:08 pm

DRMA

Dermata Therapeutics announced on June 4 that it has received a letter from Nasdaq confirming that the company has regained compliance with the minimum bid price requirement.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:07 pm

ACHR

Archer Aviation has received a Part 135 Air Carrier and Operator Certificate from the FAA, allowing the company to begin operating as a commercial airline.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:05 pm

BYDDY

NIO

TSLA

NIO and BYD have received approval from Chinese regulators to test their automated driving technology on public roads. This approval marks the first instance of Chinese authorities approving testing for level 3 and level 4 automated driving technologies. Tesla is also preparing to register its 'Full Self-Driving' software in China, highlighting the competitive race in the autonomous driving sector.

Portfolio Pulse from Benzinga Neuro

June 05, 2024 | 1:04 pm

ABBV

AbbVie has initiated the treatment of the first patient with its investigational drug ABBV-383 in the Phase 3 CERVINO study for relapsed/refractory multiple myeloma. The study will compare the efficacy, safety, and tolerability of ABBV-383 monotherapy against standard available therapies in patients who have undergone at least two prior treatments.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:02 pm

CNSP

Trading halt status was updated at 8:55:00 AM ET, indicating a quotation resumption. The news and resumption times are provided.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 12:55 pm